Table 3.
Effects of pioglitazone and placebo on individual components of the composite endpoints and total events during the study
| Endpoint | Primary composite | Secondary composite | Total events | |||
|---|---|---|---|---|---|---|
| Pioglitazone | Placebo | Pioglitazone | Placebo | Pioglitazone | Placebo | |
| Any event | 514 | 572 | 301 | 358 | 803 | 900 |
| Death | 110 | 122 | 129 | 142 | 177 | 186 |
| Non-fatal (excl silent MI) | 85 | 95 | 90 | 116 | 108 | 132 |
| Silent MI | 20 | 23 | — | — | 23 | 25 |
| Stroke | 76 | 96 | 82 | 100 | 92 | 119 |
| Major leg amputation | 9 | 15 | — | — | 28 | 28 |
| ACS | 42 | 63 | — | — | 65 | 78 |
| Coronary revascularization | 101 | 101 | — | — | 195 | 240 |
| Leg revascularization | 71 | 57 | — | — | 115 | 92 |
Abbreviations: ACS, acute coronary syndrome; MI, myocardial infarction.